We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Endologix LLC is a global medical device company dedicated to improving patients’ lives by providing innovative thera... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Disruptive Endovascular Solution Offers Minimally Invasive Alternative for Femoropopliteal Bypass Procedure

By HospiMedica International staff writers
Posted on 10 May 2023
Print article
Image: DETOUR System has won the MedTech Medical Device Engineering Breakthrough award (Photo courtesy of Endologix)
Image: DETOUR System has won the MedTech Medical Device Engineering Breakthrough award (Photo courtesy of Endologix)

Currently, the "gold standard" treatment for patients with long blockages in the superficial femoral artery (SFA) is the invasive open femoropopliteal bypass. Endovascular techniques employed for these blockages often have high complication rates. Now, a new system offers patients an alternative treatment method, combining the advantages of both open and endovascular procedures.

The DETOUR System, developed by Endologix LLC (Irvine, CA, USA), enables Percutaneous Transmural Arterial Bypass (PTAB), a unique therapy that delivers a fully percutaneous femoropopliteal bypass through the femoral vein. Designed to treat patients with moderate to severe peripheral arterial disease and long SFA blockages, the DETOUR System employs the ENDOCROSS Device and TORUS Stent Graft.

The DETOUR2 Investigational Device Exemption (IDE) study showcased a 12-month primary patency rate of 72.1% in SFA lesions with an average length of 32.7cm. Notably, the trial achieved a 100% technical success rate in 202 patients, along with a 30-day Major Adverse Event Rate of 7%. This composite outcome includes death, CD-TLR, target limb amputation, symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and the requirement for transfusion of packed red blood cells (PBRC) during the index procedure. The average hospital stay was just 1.1 days. The DETOUR System, currently an investigational device that has received FDA Breakthrough Device Designation, was recognized as the "Medical Device Engineering Breakthrough" winner at the 7th annual MedTech Breakthrough Awards.

“This award from MedTech Breakthrough is another strong validation of our strategy to expand our product portfolio into the large peripheral vascular market opportunity. Patients with long SFA blockages face tradeoffs with current treatment options. We know that open surgery of any kind is associated with complications that can negatively affect patient quality-of-life,” said Matt Thompson, MD, President and CEO of Endologix. “What makes PTAB with the DETOUR System truly unique is that, as demonstrated in our IDE study's 12-month results, it offers a minimally invasive therapy with comparable patency to open surgery while avoiding many of the complications associated with more invasive procedures. Once approved, the DETOUR System will offer a fully percutaneous femoropopliteal bypass and will provide a disruptive, innovative therapy for the treatment of long-segment SFA disease, thereby expanding the treatment options available for these patients.”

“While open surgery is still technically the gold standard for long-term durability, the reality is that not every patient is a candidate for that procedure and it can carry more risk for the patient,” said James Johnson, managing director, MedTech Breakthrough. “The DETOUR System has the potential to introduce a minimally invasive alternative for patients in need of a femoropopliteal bypass. The breakthrough solution may offer the best of both worlds: a durable, minimally invasive endovascular solution with the patency of open femoropopliteal bypass. The low MAE rate, coupled with good primary patency, provides supportive evidence for the feasibility of this new technology in a challenging patient population. Congratulations to the Endologix team on being for our 2023 ‘Medical Device Engineering Breakthrough’ award.”

Related Links:
Endologix LLC

Gold Supplier
Creatinine Meter
StatSensor Xpress Creatinine Meter
Silver Supplier
Patient Simulator
PatSim 200
High-Frequency X-Ray Generator
Battery X-Ray Generator
Premium Ultrasound System
RS85 Prestige

Print article
FIME - Informa



view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Surgical Techniques

view channel
Image: RefluxStop treats acid reflux without affecting the food passageway (Photo courtesy of Implantica AG)

Breakthrough Implant Marks Paradigm Shift in Treatment of Gastroesophageal Reflux

Acid reflux, a condition characterized by the regurgitation of the stomach's acid content into the esophagus, affects approximately 400 million individuals daily, making it the second-largest treatment... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: VCM viscoelastic testing instrument provides rapid, real-time hemostasis assessment at POC (Photo courtesy of Entegrion)

Next Gen Viscoelastic Coagulation Monitor Enables Rapid Hemostasis Assessment at Patient Side

The use of viscoelastic coagulation testing is on the rise for various applications such as trauma, surgery, obstetrics, major disease management, and more. It provides crucial information not obtained... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.